Triple negative breast cancer (TNBC), i.e., ER (estrogen receptor)-, PR (progesterone receptor)-, and HER-2 (human epithelial growth factor receptor-2)-, accounting for 15−20% in breast cancer, is a highly aggressive subtype with a significantly inferior prognosis than non-TNBC1. Here, ESR1 is linked to triple-negative breast carcinoma.